Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation

被引:0
|
作者
Osamu Yamazaki
Yoshifumi Ubara
Tatsuya Suwabe
Shohei Nakanishi
Junichi Hoshino
Naoki Sawa
Noriko Hayami
Masayuki Yamanouchi
Fumi Takemoto
Takaichi Kenmei
Kazuhiro Masuoka
Kenichi Oohashi
机构
[1] Toranomon Hospital,Nephrology Center
[2] Toranomon Hospital,Department of Hematology
[3] Toranomon Hospital,Department of Pathology
来源
关键词
AL amyloidosis; Autologous peripheral blood stem cell transplantation; SCT; High-dose melphalan; Proteinuria; VAD (vincristine, doxorubicin, and dexamethasone);
D O I
暂无
中图分类号
学科分类号
摘要
We report a 58-year-old Japanese man with primary systemic AL amyloidosis who achieved disappearance of proteinuria including Bence-Jones protein (λ-type) after two courses of VAD therapy (vincristine, doxorubicin, and dexamethasone) and subsequent high-dose melphalan, followed by autologous peripheral blood stem cell transplantation. Because this patient did not have any apparent amyloidosis-related heart or liver damage and met all of the eligibility criteria for this therapy, this treatment was performed. Both proteinuria and M-protein disappeared completely, and he is doing well clinically at 19 months after treatment. However, amyloid deposits were still found in the kidneys, including the glomeruli and tubulointerstitium, when renal biopsy was done at 8 months after treatment. In the future, we may reach a time when clinical remission corresponds to histological remission.
引用
收藏
页码:522 / 525
页数:3
相关论文
共 50 条
  • [41] High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers
    Paul S. White
    Pooja Phull
    Dina Brauneis
    J. Mark Sloan
    Karen Quillen
    Shayna Sarosiek
    Vaishali Sanchorawala
    Bone Marrow Transplantation, 2018, 53 : 1593 - 1595
  • [42] High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers
    White, Paul S.
    Phull, Pooja
    Brauneis, Dina
    Sloan, J. Mark
    Quillen, Karen
    Sarosiek, Shayna
    Sanchorawala, Vaishali
    BONE MARROW TRANSPLANTATION, 2018, 53 (12) : 1593 - 1595
  • [43] Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis
    Nguyen, Vina P.
    Landau, Heather
    Quillen, Karen
    Brauneis, Dina
    Shelton, Anthony C.
    Mendelson, Lisa
    Rahman, Hafsa
    Sloan, J. Mark
    Sarosiek, Shayna
    Sanchorawala, Vaishali
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (09) : 1823 - 1827
  • [44] High dose intravenous melphalan and autologous stem cell transplantation for the treatment of AL amyloidosis: Morbidity and mortality.
    Sanchorawala, V
    Taper, J
    Seldin, DC
    Falk, RH
    Dember, L
    Berk, J
    Finn, K
    Quillen, K
    Skinner, M
    Wright, DG
    BLOOD, 2001, 98 (11) : 860A - 860A
  • [45] Reversal of the neuropathy in primary (AL) amyloidosis following treatment with high-dose melphalan and stem cell rescue
    Bergethon, PR
    Skinner, M
    Simms, RW
    Comenzo, RL
    NEUROLOGY, 1996, 46 (02) : 6069 - 6069
  • [46] High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
    Skinner, M
    Sanchorawala, V
    Seldin, DC
    Dember, LM
    Falk, RH
    Berk, JL
    Anderson, JJ
    O'Hara, C
    Finn, KT
    Libbey, CA
    Wiesman, J
    Quillen, K
    Swan, N
    Wright, DG
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (02) : 85 - 93
  • [47] Erratum: Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis
    V Sanchorawala
    D G Wright
    K Quillen
    K T Finn
    L M Dember
    J L Berk
    G Doros
    C Fisher
    M Skinner
    D C Seldin
    Bone Marrow Transplantation, 2007, 40 (6) : 607 - 607
  • [48] HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN AMYLOIDOSIS-AL
    MAJOLINO, I
    MARCENO, R
    PECORARO, G
    SCIME, R
    VASTA, S
    LIBERTI, G
    RIZZO, A
    INDOVINA, A
    CARONIA, F
    HAEMATOLOGICA, 1993, 78 (01) : 68 - 71
  • [49] High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement
    Shimojima, Y
    Matsuda, M
    Ishii, W
    Koyama, J
    Yamamoto, K
    Shimodaira, S
    Sakashita, K
    Koike, K
    Ikeda, S
    INTERNAL MEDICINE, 2005, 44 (05) : 484 - 489
  • [50] Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
    Sanchorawala, V
    Seldin, DC
    Magnani, B
    Skinner, M
    Wright, DG
    BONE MARROW TRANSPLANTATION, 2005, 36 (07) : 597 - 600